Clinical trials: Rivaroxaban
Atrial Fibrillation, Anticoagulant Adverse Reaction
Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.
- Conditions
- Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke, Major Adverse Cardiac Events
- Trial name
- NCT06108414
- Testing
- low-dose rivaroxaban, Standard-dose rivaroxaban
- Where
- China
- Volunteers
- 4,374 people
- Sponsor
- China National Center for Cardiovascular Diseases
Stable Angina, Unstable Angina
COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
Prospective, multi-centre, randomized, open-label, parallel comparisons to evaluate the incidence of bleedings (COSTA-Bleed) and the incidence of ischemic and bleeding events (COSTA-Outcome) following a therapy with the abluminal…
- Conditions
- Stable Angina, Unstable Angina, STEMI, NSTEMI
- Trial name
- COSTA (NCT02723981)
- Testing
- COMBO-Stent, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran, Any drug eluting stent oder bare metal sent
- Where
- 10 sites in Germany
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Stroke, Atrial Fibrillation
Efficacy and Safety of Oral Anticoagulants Among Thai Octogenarians With Nonvalvular Atrial Fibrillation
A retrospective cohort study of Thai octogenarians with nonvalvular atrial fibrillation (NVAF) initiating apixaban, dabigatran, rivaroxaban or warfarin was conducted in medical school hospital in Thailand.
- Trial name
- NCT04047654
- Testing
- Non vitamin K oral anticoagulants
- Where
- Thailand
- Volunteers
- 327 people
- Sponsor
- Mahidol University
Ischaemic Stroke
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
When to start anticoagulation in patients with an acute ischaemic stroke and atrial fibrillation (AF) is a relevant unanswered question in clinical practice.
- Trial name
- ELAN (NCT03148457)
- Testing
- Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®), Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
- Where
- 98 sites in Austria, Belgium and 13 more
- Volunteers
- 2,013 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Healthy
A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
The purpose of this study is to assess the use of 2 different Prothrombin Complex Concentrates (PCCs) on their ability to reverse (normalize) the pharmacodynamic effects of rivaroxaban in healthy adult volunteers.
- Trial name
- NCT01656330
- Testing
- Rivaroxaban 20 mg twice daily, Rivaroxaban 20 mg once daily, Profilnine SD
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Deep Vein Thrombosis
Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
The treatment of isolated distal deep vein thrombosis remains one of the most debated issues in the field of venous thromboembolism and only very few studies have directly addressed the issue of treatment in objectively confirmed…
- Trial name
- RIDTS (NCT02722447)
- Testing
- rivaroxaban
- Where
- 7 sites in Italy
- Volunteers
- 1,100 people
- Sponsor
- Walter Ageno
Atrial Fibrillation
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).
- Trial name
- NCT02792335
- Testing
- apixaban, dabigatran, rivaroxaban
- Volunteers
- 28,000 people
- Sponsor
- Bristol-Myers Squibb
Limb Ischemia
Comparison of Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin in Chronic Limb-Threatening Ischemia
The goal of this clinical trial is to compare the effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone in patients aged 40-70 years with chronic limb-threatening ischemia, diabetes mellitus, hypertension, and…
- Trial name
- NCT07832578
- Testing
- Aspirin tablet, Low-Dose Rivaroxaban Plus Aspirin,
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- King Edward Medical University
Pulmonary Embolism, Venous Thrombosis
XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
The trial is an open-label, randomized, trial examining novel biomarkers of thrombosis in patients managed with rivaroxaban vs. standard care following treatment of pulmonary embolism (PE) with catheter-guided alteplase.
- Trial name
- XENITH (NCT02506985)
- Testing
- rivaroxaban, warfarin
- Volunteers
- 10 people
- Sponsor
- Susan Smyth
Acute Pulmonary Embolism
Mechanical Thrombectomy for Acute Pulmonary Embolism
Research Objective: To prospectively compare the efficacy and safety of a pre-collaboratively developed ultra-thin PTFE minimally invasive thrombectomy system versus standard pharmacological therapy in patients with acute…
- Trial name
- NCT07032025
- Testing
- Innovative Device Group, Standard Pharmacological Therapy Group
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Atrial Fibrillation
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
The purpose of this study is to look at how many patients with AF had strokes, major bleeding and death in both people who had and had not taken any oral anticoagulant.
- Trial name
- SIFNOS (NCT05838664)
- Testing
- No OAC, VKA, apixaban
- Where
- France
- Volunteers
- 2,140,403 people
- Sponsor
- Pfizer
ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban.
- Trial name
- NCT07195812
- Testing
- Dual Antiplatelet (DAPT) Therapy, Rivaroxaban
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Thrombosis, Deep Vein Thrombosis
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common post-operative complication.
- Conditions
- Thrombosis, Deep Vein Thrombosis, Surgery--Complications
- Trial name
- NCT03483181
- Testing
- Xarelto (rivaroxaban), Lovenox (enoxaparin)
- Where
- Vietnam
- Sponsor
- Hanoi Medical University
Atrial Fibrillation
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
1. The recent development of novel oral anticoagulants (NOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could potentially overcome many drawbacks of…
- Trial name
- DARING-AF (NCT02666157)
- Testing
- Dabigatran etexilate, Rivaroxaban, Apixaban
- Where
- 5 sites in Taiwan
- Volunteers
- 3,672 people
- Sponsor
- National Cheng-Kung University Hospital
Antiphospholipid Antibody Syndrome
Rivaroxaban for Antiphospholipid Antibody Syndrome
The antiphospholipid antibody syndrome (APS) is a syndrome associated with excessive blood clotting (thrombosis). APS is among the most common cause of heart attack and stroke in patients under the age of 50 and is particularly…
- Trial name
- RAPS (NCT02116036)
- Testing
- Rivaroxaban
- Where
- 6 sites in Canada
- Volunteers
- 81 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Rheumatic Heart Disease
INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
This program is a comprehensive evaluation of rheumatic valvular heart disease (RVHD), Atrial fibrillation (AF)/flutter and stroke.
- Trial name
- INVICTUS-ASA (NCT02832531)
- Testing
- Rivaroxaban (15 mg), Aspirin
- Sponsor
- Population Health Research Institute
Deep Venous Thrombosis
Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study
This prospective outcome study is designed to assess the safety of rivaroxaban in the pre-diagnosis phase of DVT.
- Trial name
- Ri-Schedule (NCT02486445)
- Testing
- Rivaroxaban
- Where
- Norway
- Volunteers
- 625 people
- Sponsor
- Ostfold Hospital Trust
Peripartum Cardiomyopathy, Postpartum
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and…
- Trial name
- REBIRTH (NCT05180773)
- Testing
- Bromocriptine, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban
- Where
- 64 sites in United States
- Volunteers
- 250 people
- Sponsor
- Dennis M. McNamara, MD, MS
Non-paroxysmal Atrial Fibrillation
LAA Clipping Versus NOACs to Prevent Stroke in Non-paroxysmal Atrial Fibrillation.
This trial is designed to examine the hypothesis that thoracoscopic LAA clipping is superior to NOACs for stroke, systemic embolism, all-cause mortality, major bleeding events and clinically relevant nonmajor bleeding events in…
- Trial name
- NCT06021808
- Testing
- Thoracoscopic LAA clipping, Novel oral anticoagulant
- Where
- China
- Volunteers
- 290 people
- Sponsor
- China National Center for Cardiovascular Diseases
Non-valvular Atrial Fibrillation, Acute Coronary Syndrome
Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI
This study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in Germany.
- Conditions
- Non-valvular Atrial Fibrillation, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Antithrombotic Therapy
- Trial name
- RIVA-PCI (NCT03315650)
- Where
- 13 sites in Germany
- Volunteers
- 1,632 people
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung